Entries by Maren Kühr

Trump’s win will affect the biotechnology sector

During the conference calls on the latest quarterly reports, several recurring questions emerged: What consequences do you anticipate if Trump is to be re-elected? How will tariffs affect supply chains and operating profits? What about FDA, IRA, the healthcare system, or the bioeconomy strategy?

The golden age of engineered therapeutic antibodies

Therapeutic antibodies today represent a cornerstone of the treatment of various diseases including cancer, infectious, autoimmune, cardiovascular, haematological, metabolic, neurologic and ocular diseases, and make up a major proportion of blockbuster drugs with global sales of more than US$230bn in 2023.

New CEO appointed

Matt Gunnison was appointed as the new CEO of Biosynth, headquartered in Staad (CH). He started in November.

Experienced CMO on board

The French biotech company DiogenX is further strengthening its management team. In November, Dr Klara Owen was appointed as Chief Medical Officer.

Aequorin: superior choice for GPCR calcium signalling

The study of G protein-coupled receptor (GPCR) signalling is crucial for ­understanding a wide range of physiological processes. Among the methods used to monitor ­calcium ­signalling, Aequorin stands out for its high sensitivity, specificity, and sub-cellular compartment ­targeting. While many CROs are still using fluorescent calcium dyes, EuroscreenFast is making use of Aequorin’s unique properties as an invaluable tool to delve into the complexities of cellular communication.

CEO and Chairman of the Executive Board

French Innate Pharma SA announced the appointment of Jonathan Dickinson as the Company’s newChief Executive Officer (CEO) and Chairman of the Executive Board. He succeeds Hervé Brailly, co-founder of the Company, who was interim CEO, during the search process.